Laurion Capital Management LP Vertex Pharmaceuticals Inc Transaction History

Laurion Capital Management LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$392.81 - $485.53 $25.8 Million - $31.9 Million	-65,645 Reduced 98.13%	1,248 $584,000
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $27.3 Million - $29.8 Million	66,893 New	66,893 $28 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $193,050 - $215,398	705 New	705 $204,000
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $2.81 Million - $3.5 Million	-11,949 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $2.65 Million - $3.12 Million	11,949 New	11,949 $3.12 Million
Q4 2020 Feb 12, 2021	SELL	$207.01 - $276.09 $15.3 Million - $20.4 Million	-73,975 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$255.65 - $303.1 $18.9 Million - $22.4 Million	73,975 New	73,975 $20.1 Million
Q4 2019 Feb 13, 2020	SELL	$166.71 - $223.91 $445,949 - $598,959	-2,675 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$166.23 - $187.09 $444,665 - $500,465	2,675 New	2,675 $453,000
Q4 2017 Feb 13, 2018	SELL	$137.28 - $155.55 $782,496 - $886,635	-5,700 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$148.13 - $162.24 $844,341 - $924,768	5,700	5,700 $867,000

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.